6 completed, 4 active not recruiting, 2 not yet recruiting, 1 unknown. 6 Phase 1, 4 Phase 3, 2 Phase 2, 2 Phase 4.
By phase and status
Follow PCV20: new trials by email Literature Review of PCV20 trials Research Report on PCV20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial Phase 1 Not yet recruiting 60 2027-01-25 2026-07-16 A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial Phase 1 Active not recruiting 46 2026-05-15 2026-09-28 Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial Phase 1 Active not recruiting 122 2026-03-10 2026-10-27 Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination 31-valent pneumococcal conjugate vaccine, PCV20 - Pneumococcal Vaccines Phase 3 Active not recruiting 752 2026-02-09 2026-06-30 Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 - Pneumococcal Disease Phase 3 Completed 4049 2025-12-01 2026-10-16 A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial Phase 1 Completed 127 2025-08-12 2026-06-05 Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax Adjuvant PCV-LITE, PCV-LITE+LVA, PCV20 - Vaccine Reaction Phase 1 Not yet recruiting 80 2025-07-01 2025-05-22 Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine - Pneumococcal Vaccines Phase 1 / Phase 2 Completed 1015 2023-11-08 2025-07-28 Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy PCV20 - Lymphoma Phase 4 Active not recruiting 30 2023-10-06 2026-09-15 Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults RSVPreF3 OA investigational vaccine, PCV20 - Respiratory Syncytial Virus Infections Phase 3 Completed 1113 2023-05-26 2025-05-18 Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years NVX, PCV20, Placebo - COVID-19, Pneumococcal Infections Phase 4 Unknown 256 2023-03-01 2023-03-15 Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3) V116, PCV20 - Pneumococcal Infection Phase 3 Completed 2663 2022-07-13 2024-10-26 A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants AFX3772, Prevnar 13, Prevnar 20 - Pneumonia, Bacterial, Pneumococcal Infections Phase 2 Completed 388 2022-06-16 2026-10-09
Conditions studied Pneumococcal Infections (5) · Pneumonia, Bacterial (5) · Pneumonia (3) · COVID-19 (1) · Infections (1) · Lymphoma (1) · Pneumonia, Pneumococcal (1) · Respiratory Syncytial Virus Infections (1) · Streptococcal Infections (1)
Sponsors GlaxoSmithKline (6) · Vaxcyte, Inc. (3) · LiteVax BV (1) · M.D. Anderson Cancer Center (1) · Medical University of Vienna (1) · Merck Sharp & Dohme LLC (1)
Countries United States (7) · Australia (3) · Belgium (2) · Puerto Rico (2) · Chile (1) · Germany (1) · New Zealand (1) · Poland (1) · South Africa (1) · South Korea (1) · Spain (1) · Sweden (1) · Taiwan (1) · Turkey (Türkiye) (1)
Top investigators Fareed Khawaja, MD (1)
Results publications PMID 38964361 , PMID 39756693 , PMID 41864214 , PMID 41994955
NIH funding 2023 (1)